SIMABS
ActiveSummary
The annual accounts of SIMABS for fiscal year 2025 show a net loss of 55% of total assets. The 2025 annual accounts show equity of €1.0m and a net result of -€1.5m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 38% of 65 sector peers (fiscal year 2025). The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.5% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability0=
Solvency63▲+63
Growth52▲+20
Track record100
Bankruptcy probability, 12 months
1.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €50,000 at 30 days only on tighter terms
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity ample (current ratio 1.5 against 1.67 in 2024; short-term debt: 51.4% and cash: 36.4% of total assets), but 62.4% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
1 d early
2024
8 d early
2023
2 d early
2022
1 d early
2021
28 d early
2020
23 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 11 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
27-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Public money How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
In the rankings
#6 company by total assets in Diepenbeek, Manufacturing sector#8 company by equity in Diepenbeek, Manufacturing sector
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€1.5m▼ 49.4%
2024 · -€986,869
Working capital
€692,436▲ 151%
2024 · €276,163
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€358,205-€744,370▼ 108%-€436,235▲ 41.4%-€963,957▼ 121%-€1.4m▼ 49.8%
Net result-€370,847below the sector's middle half-€768,099below the sector's middle half▼ 107%-€453,195below the sector's middle half▲ 41.0%-€986,869below the sector's middle half▼ 118%-€1.5mbelow the sector's middle half▼ 49.4%
Equity€1.0mwithin the sector's middle half▲ 24.4%€271,415within the sector's middle half▼ 73.9%€649,820above the sector's middle half▲ 139%-€337,049below the sector's middle half€1.0mwithin the sector's middle half
Total assets€2.2mwithin the sector's middle half▲ 62.6%€1.2mwithin the sector's middle half▼ 46.8%€1.4mabove the sector's middle half▲ 20.1%€1.1mwithin the sector's middle half▼ 22.1%€2.7mwithin the sector's middle half▲ 140%
Debt€1.2m▲ 122%€915,689▼ 23.2%€776,460▼ 15.2%€1.4m▲ 86.5%€1.7m▲ 15.0%
Working capital€687,707▼ 40.5%€135,873▼ 80.2%€458,929▲ 238%€276,163▼ 39.8%€692,436▲ 151%
Solvency46.6%within the sector's middle half▼ 14.3pp22.9%within the sector's middle half▼ 23.7pp45.6%within the sector's middle half▲ 22.7pp-30.3%below the sector's middle half▼ 75.9pp37.6%within the sector's middle half▲ 67.9pp
Staff (FTE)3▲ 131%4.4within the sector's middle half▲ 46.7%4▼ 9.1%7.3above the sector's middle half▲ 82.5%11.4within the sector's middle half▲ 56.2%
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2024 Net result -118% on 2023. The accounts now follow the abbreviated schema, last year the micro schema.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €1.4m in 2025 against €963,957 in 2024; the loss grows and 2025 has the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.7m
Fixed assets
€604,030 ▲ 43.0%
Current assets
€2.1m ▲ 200%
Equity and liabilities €2.7m
Equity
€1.0m
Debt
€1.7m
Debt finances 62.4% of the balance-sheet total.
Key figures and ratios
EBITDA
-€1.2m▼
2024 · -€768,012
Cash flow
-€1.3m▼
2024 · -€790,924
Current ratio
1.50▼
2024 · 1.67
Quick ratio
1.45▼
2024 · 1.50
Debt to equity
1.66▲
2024 · -4.30
ROE
-147.0%
ROA
-55.3%▲
2024 · -88.8%
Interest coverage
-42.86▼
2024 · -32.61
Debt ≤ 1 year
€1.4m▲
2024 · €412,265
Debt > 1 year
€261,730▼
2024 · €777,162
Income taxes
€2,065▲
2024 · €1,111
Staff costs
€1.1m▲
2024 · €661,307
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 224 companies that looked in July 2024 the way this one looks now, 4.0% went bankrupt within 24 months and 88% are still going.
- Small
- 5 to 10 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
4.0%
went bankrupt
7.1%
stopped otherwise
88%
still going
A further 0.9% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 1.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 224 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | €1,778 | - | €196 | €0 | ▼ 100% |
| Remuneration, social security and pensions62 | €186,408 | €333,246 | €363,862 | €661,307 | €1.1m | ▲ 65.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €50,900 | €172,149 | €191,411 | €195,945 | €211,286 | ▲ 7.8% |
| Other operating charges640/8 | €512 | €2,106 | €2,247 | €1,516 | €11,742 | ▲ 675% |
| Gross operating margin9900 | -€120,385 | -€236,868 | €121,285 | -€105,189 | -€129,335 | ▼ 23.0% |
| Operating profit (loss)9901 | -€358,205 | -€744,370 | -€436,235 | -€963,957 | -€1.4m | ▼ 49.8% |
| Financial income75/76B | €99 | €19 | €718 | €1,752 | €316 | ▼ 81.9% |
| Recurring financial income75 | €99 | €19 | €718 | €1,752 | €316 | ▼ 81.9% |
| Financial charges65/66B | €12,568 | €23,262 | €17,103 | €23,553 | €28,766 | ▲ 22.1% |
| Recurring financial charges65 | €12,568 | €23,262 | €17,103 | €23,553 | €28,766 | ▲ 22.1% |
| Profit (loss) for the period before taxes9903 | -€370,675 | -€767,612 | -€452,620 | -€985,758 | -€1.5m | ▼ 49.4% |
| Income taxes67/77 | €172 | €487 | €574 | €1,111 | €2,065 | ▲ 86.0% |
| Profit (loss) for the period9904 | -€370,847 | -€768,099 | -€453,195 | -€986,869 | -€1.5m | ▼ 49.4% |
| Profit (loss) for the period to be appropriated9905 | -€370,847 | -€768,099 | -€453,195 | -€986,869 | -€1.5m | ▼ 49.4% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €2.2m | €1.2m | €1.4m | €1.1m | €2.7m | ▲ 140% |
| Fixed assets21/28 | €850,535 | €736,874 | €545,424 | €422,450 | €604,030 | ▲ 43.0% |
| Intangible fixed assets21 | - | €14,349 | €10,784 | €7,218 | €3,653 | ▼ 49.4% |
| Tangible fixed assets22/27 | €844,295 | €716,226 | €528,380 | €395,181 | €580,326 | ▲ 46.9% |
| Plant, machinery and equipment23 | €570,401 | €102,766 | €77,631 | €96,615 | €425,265 | ▲ 340% |
| Furniture and vehicles24 | €841 | €626 | €412 | €197 | €0 | ▼ 100% |
| Leasing and similar rights25 | €273,054 | €612,833 | €450,338 | €287,842 | €146,708 | ▼ 49.0% |
| Other tangible fixed assets26 | - | - | - | €10,527 | €8,354 | ▼ 20.6% |
| Financial fixed assets28 | €6,240 | €6,300 | €6,260 | €20,051 | €20,051 | = |
| Current assets29/58 | €1.4m | €450,229 | €880,856 | €688,428 | €2.1m | ▲ 200% |
| Amounts receivable after more than one year29 | - | - | - | - | €320,000 | - |
| Other amounts receivable291 | - | - | - | - | €320,000 | - |
| Stocks and contracts in progress3 | €48,459 | €58,834 | €58,274 | €69,754 | €69,754 | = |
| Stocks30/36 | €48,459 | €58,834 | €58,274 | €69,754 | €69,754 | = |
| Amounts receivable within one year40/41 | €43,099 | €47,154 | €149,855 | €455,908 | €682,535 | ▲ 49.7% |
| Trade receivables40 | €517 | €27,931 | €149,562 | €378,458 | €156,513 | ▼ 58.6% |
| Other amounts receivable41 | €42,583 | €19,222 | €293 | €77,450 | €526,022 | ▲ 579% |
| Cash at bank and in hand54/58 | €826,150 | €342,342 | €672,241 | €162,766 | €970,589 | ▲ 496% |
| Deferred charges and accrued income490/1 | €464,328 | €1,900 | €486 | €0 | €21,866 | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €2.2m | €1.2m | €1.4m | €1.1m | €2.7m | ▲ 140% |
| Equity10/15 | €1.0m | €271,415 | €649,820 | -€337,049 | €1.0m | ▲ 398% |
| Contributions10/11 | €1.1m | €1.1m | €1.9m | €1.9m | €4.7m | ▲ 148% |
| Capital10 | €1.1m | €1.1m | €1.9m | €1.9m | €4.7m | ▲ 148% |
| Issued capital100 | €1.1m | €1.1m | €1.9m | €1.9m | €4.7m | ▲ 148% |
| Reserves13 | €50,000 | €50,000 | €50,000 | €50,000 | €50,000 | = |
| Non-distributable reserves130/1 | €50,000 | €50,000 | €50,000 | €50,000 | €50,000 | = |
| Legal reserve130 | €50,000 | €50,000 | €50,000 | €50,000 | €50,000 | = |
| Profit (loss) carried forward14 | -€85,486 | -€853,585 | -€1.3m | -€2.3m | -€3.8m | ▼ 64.3% |
| Amounts payable17/49 | €1.2m | €915,689 | €776,460 | €1.4m | €1.7m | ▲ 15.0% |
| Amounts payable after more than one year17 | €498,727 | €601,333 | €354,533 | €777,162 | €261,730 | ▼ 66.3% |
| Financial debts170/4 | €498,727 | €601,333 | €354,533 | €777,162 | €261,730 | ▼ 66.3% |
| Amounts payable within one year42/48 | €694,330 | €314,357 | €421,927 | €412,265 | €1.4m | ▲ 233% |
| Current portion of amounts payable after more than one year42 | €163,514 | €242,279 | €246,800 | €209,364 | €128,736 | ▼ 38.5% |
| Trade debts44 | €507,406 | €28,641 | €106,467 | €129,211 | €1.1m | ▲ 782% |
| Suppliers440/4 | €507,406 | €28,641 | €106,467 | €129,211 | €1.1m | ▲ 782% |
| Taxes, remuneration and social security45 | €23,409 | €43,437 | €68,660 | €73,690 | €104,043 | ▲ 41.2% |
| Taxes450/3 | €196 | €487 | €26,156 | €1,708 | €3,773 | ▲ 121% |
| Remuneration and social security454/9 | €23,213 | €42,950 | €42,504 | €71,982 | €100,270 | ▲ 39.3% |
| Accrued charges and deferred income492/3 | - | - | - | €258,500 | €31,485 | ▼ 87.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€370,847 | -€768,099 | -€453,195 | -€986,869 | -€1.5m | ▼ 49.4% |
| + Depreciation and write-downs630 | €50,900 | €172,149 | €191,411 | €195,945 | €211,286 | ▲ 7.8% |
| Operating cash flow (approximation) | -€319,947 | -€595,950 | -€261,784 | -€790,924 | -€1.3m | ▼ 59.7% |
| Investment in fixed assets (approximation) | - | -€58,489 | €40 | -€72,971 | -€392,865 | ▼ 438% |
| Change in cash | - | -€483,808 | €329,899 | -€509,475 | €807,823 | ▲ 259% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
30-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Weakest financial yearnet -€1.5m
Net result drops to -€1.5m, the lowest in the series.
31-12
Financial
Equity above €1mEq €1.0m
Equity rises from -€337,049 to €1.0m.
23-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
29-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Equity above €500,000Eq €649,820 ▲139%
Equity rises from €271,415 to €649,820.
30-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
03-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Equity above €1mEq €1.0m ▲24.4%
Equity rises from €835,361 to €1.0m.
08-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 9 acts read
About the unread acts
We know of 9 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
9 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Diepenbeek · 2 establishment units since 2019
Ground area
2.8 ha
Building footprint
595 m²
Volume, LiDAR
3,890 m³
2 parcels, Flanders · tallest building 7.4 m, ±2 floors. Linked by address, not a title deed.
2 establishment units
SIMABS
since 20192.292.355.864
SIMABS
since 20252.378.436.337
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71011A0272/00F000 | Flanders | 2.5 ha | - | - |
| 71011A0098/00L000 | Flanders | 2,465 m² | 1 · 595 m² | 7.4 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
3 ownersOwners 3
-
37.08%
-
18.54%
-
2.91%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Public money · subsidies and aid
Flemish government
2024 to 2025 · 6 entries · 549,154 EUR awarded · 440,917 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 5 | 14,917 EUR | 227,917 EUR |
| 2024 | 1 | 534,237 EUR | 213,000 EUR |
Similar companies · same sector, comparable size
Axo Industry International
BE 0859.791.271
Wavre · Eq €940,443
PHENIX PROPERTY
BE 0413.676.987
Hoogstraten · Eq €934,134
OROTECH
BE 0877.916.118
Temse · Eq €882,289
BIVIT
BE 0439.165.025
Wevelgem · Eq €780,157
TRUVION HEALTHCARE
BE 0414.047.864
Temse · Eq €1.3m
Of 148 companies in sector 21201 we hold annual accounts for 116. 60 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded20-08-2019
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
72101Research and development on biotechnology
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
Contact
Website
www.simabs.com
E-mail
info@simabs.com
E-invoicing
Reachable via Peppol
Peppol ID
0208:0732709096
Also
9925:BE0732709096
Registered
25-11-2025
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.